Matthew M Weiss

6PUBLICATIONS
27CO-AUTHORS
FermentationCharacterisation of biological macromoleculesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 23, 2026
Structural basis for selective and potent degradation of IRAK4 by KT-474.

|Dec 09, 2024
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors.

Yogesh K Chutake, Michele F Mayo, Nancy Dumont

|Aug 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.

Xiaozhang Zheng, Nan Ji, Veronica Campbell

|Jun 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma.

Matthew M Weiss, Xiaozhang Zheng, Nan Ji

|Mar 22, 2017
Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity.

Russell F Graceffa, Alessandro A Boezio, Jessica Able

|Mar 14, 2017
Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities.

Matthew M Weiss, Thomas A Dineen, Isaac E Marx

Pageof 1

Frequent Collaborators

2 joint publications

Isaac E Marx

2 joint publications

Russell Graceffa

1 joint publications

Howard Bregman

1 joint publications

Xiaozhang Zheng